Katherine A. Janeway

12.6k total citations · 1 hit paper
148 papers, 4.5k citations indexed

About

Katherine A. Janeway is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Neurology. According to data from OpenAlex, Katherine A. Janeway has authored 148 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Pulmonary and Respiratory Medicine, 40 papers in Cancer Research and 35 papers in Neurology. Recurrent topics in Katherine A. Janeway's work include Sarcoma Diagnosis and Treatment (87 papers), Cancer Genomics and Diagnostics (33 papers) and Neuroblastoma Research and Treatments (32 papers). Katherine A. Janeway is often cited by papers focused on Sarcoma Diagnosis and Treatment (87 papers), Cancer Genomics and Diagnostics (33 papers) and Neuroblastoma Research and Treatments (32 papers). Katherine A. Janeway collaborates with scholars based in United States, Canada and France. Katherine A. Janeway's co-authors include Richard Görlick, Holcombe E. Grier, Alberto S. Pappo, Michael W. Bishop, Steven G. DuBois, Neyssa Marina, Mark Krailo, R. Lor Randall, Antonio R. Pérez‐Atayde and Ryan D. Roberts and has published in prestigious journals such as Science, Circulation and Journal of Clinical Oncology.

In The Last Decade

Katherine A. Janeway

141 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osteosarcoma

2022 337 citations Katherine A. Janeway, Ryan D. Roberts et al. profile →

Peers

Countries citing papers authored by Katherine A. Janeway

Since Specialization

Citations

This map shows the geographic impact of Katherine A. Janeway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine A. Janeway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine A. Janeway more than expected).

Fields of papers citing papers by Katherine A. Janeway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine A. Janeway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine A. Janeway. The network helps show where Katherine A. Janeway may publish in the future.

Co-authorship network of co-authors of Katherine A. Janeway

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine A. Janeway. A scholar is included among the top collaborators of Katherine A. Janeway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine A. Janeway. Katherine A. Janeway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination 2025 ·JNCI Journal of the National Cancer Institute ·Katie A. Greenzang, Kathleen Montgomery, Adam DuVall, Michael Roth, (unknown), (unknown), Lindsay A. Renfro, (unknown), John J. Doski, Kara M. Kelly, Sharon M. Castellino, Jennifer L. McNeer, Maureen M. O’Brien, Damon R. Reed, Katherine A. Janeway, Pamela S. Hinds, Sue Zupanec, Susan K. Parsons	0
2	Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group 2025 ·Pediatric Blood & Cancer ·Daniel J. Indelicato, (unknown), Safia K. Ahmed, Mark Krailo, (unknown), Allen Buxton, Odion Binitie, Alexander B. Christ, (unknown), Paul J. Chuba, Helen Nadel, Bruce Pawel, Richard Görlick, Damon R. Reed, Steven G. DuBois, Katherine A. Janeway, Patrick J. Leavey, Leo Mascarenhas, Nadia N. Laack	0
3	Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality 2024 ·Journal of Clinical Oncology ·Vinayak Venkataraman, (unknown), Bettina F. Drake, Liz Salmi, Elizabeth B. Claus, Anne Schuster, John F. P. Bridges, Heinz‐Josef Lenz, Cheryl L. Willman, Diane M. Diehl, Katherine A. Janeway, Jennifer W. Mack, Suzanne George	1
4	Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG). 2024 ·Journal of Clinical Oncology ·David S. Shulman, Kelly Klega, Allen Buxton, (unknown), Jessica Armstrong, Carrie Cibulskis, Richard Görlick, Julia Glade Bender, Damon R. Reed, Katherine A. Janeway, Steven G. DuBois, Brian D. Crompton	1
5	Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma 2023 ·Pediatric Blood & Cancer ·Kevin Campbell, (unknown), Nan Chen, Kerri L. Cavanaugh, (unknown), Katherine A. Janeway, David S. Shulman, Suzanne George, Kelly Klega, Brian D. Crompton, Wendy B. London, Steven G. DuBois	3
6	Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031 2023 ·Journal of Clinical Oncology ·Thomas F. Cash, Mark Krailo, Allen Buxton, Bruce Pawel, John H. Healey, Odion Binitie, Karen J. Marcus, Holcombe E. Grier, Patrick J. Grohar, Damon R. Reed, Aaron R. Weiss, Richard Görlick, Katherine A. Janeway, Steven G. DuBois, Richard B. Womer	6
7	A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high‐dose methotrexate therapy in open‐label trials 2023 ·Pediatric Blood & Cancer ·Katherine A. Janeway, Luis Gros, Stefan Schwartz, Claire Daugherty, (unknown), (unknown), (unknown), Suzanne M. Ward, Carmelo Rizzari	6
8	Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1 2022 ·JCO Precision Oncology ·Ellen Zhang, Amber Miller, Catherine Clinton, (unknown), Stephan D. Voss, Jon C. Aster, Alanna J. Church, Reza Rahbar, (unknown), Katherine A. Janeway, Steven G. DuBois	3
9	Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group 2022 ·European Journal of Cancer ·Pooja Hingorani, Mark Krailo, Allen Buxton, Paul R. Hutson, Paul M. Sondel, Mitchell B. Diccianni, Alice L. Yu, Carol D. Morris, Richard B. Womer, Brian D. Crompton, R. Lor Randall, Lisa A. Teot, Steven G. DuBois, Katherine A. Janeway, Richard Görlick, Michael S. Isakoff	23
10	Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes 2022 ·The American Journal of Human Genetics ·(unknown), Sabrina Y. Camp, Seunghun Han, (unknown), (unknown), (unknown), Erin L. Young, (unknown), (unknown), Trent Fowler, Alexander Gusev, Junne Kamihara, Katherine A. Janeway, Joshua D. Schiffman, Brian D. Crompton, Saud H. AlDubayan, Eliezer M. Van Allen	27
11	Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group 2021 ·Pediatric Blood & Cancer ·Anderson B. Collier, Mark Krailo, Ha Dang, Steven G. DuBois, Douglas S. Hawkins, Mark L. Bernstein, Lisa Bomgaars, Damon R. Reed, Richard Görlick, Katherine A. Janeway	13
12	Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology 2021 ·Cancer Medicine ·David S. Shulman, (unknown), Stacey L. Edwards, Catherine Clinton, Sarah K. Hunt, (unknown), (unknown), Gregory H. Reaman, Hasan Al‐Sayegh, Kira Bona, Allison F. O’Neill, Suzanne Shusterman, Katherine A. Janeway, Andrew E. Place, Susan Chi, Clement Ma, Steven G. DuBois	6
13	Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers 2020 ·Clinical Cancer Research ·Suzanne J. Forrest, Alyaa Al‐Ibraheemi, Duong Doan, Abigail Ward, Catherine Clinton, Juan Putra, (unknown), Cigall Kadoch, N. Susan, Steven G. DuBois, Patrick J. Leavey, Nicole R. LeBoeuf, Elizabeth A. Mullen, Natalie B. Collins, Alanna J. Church, Katherine A. Janeway	36
14	Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis 2020 ·Pediatric Blood & Cancer ·(unknown), Clement Ma, Katherine A. Janeway, Steven G. DuBois, David S. Shulman	4
15	Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group 2019 ·Cancer ·Ryan D. Roberts, Michael M. Lizardo, Damon R. Reed, Pooja Hingorani, Jason Glover, Wendy Allen‐Rhoades, Timothy M. Fan, Chand Khanna, E. Alejandro Sweet‐Cordero, Thomas F. Cash, Michael W. Bishop, Meenakshi Hegde, (unknown), Christian Koelsche, (unknown), David Malkin, Poul H. Sorensen, Paul S. Meltzer, Katherine A. Janeway, Richard Görlick, Brian D. Crompton	87
16	Von Hippel–Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood 2017 ·Clinical Cancer Research ·Surya P. Rednam, Ayelet Erez, Harriet Druker, Katherine A. Janeway, Junne Kamihara, Wendy Kohlmann, Katherine L. Nathanson, Lisa J. States, Gail E. Tomlinson, Anita Villani, Stephan D. Voss, Joshua D. Schiffman, Jonathan D. Wasserman	174
17	Precision medicine in pediatric oncology 2017 ·Current Opinion in Pediatrics ·Suzanne J. Forrest, Birgit Geoerger, Katherine A. Janeway	87
18	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group 2016 ·Clinical Cancer Research ·Kieuhoa T. Vo, (unknown), C. Lorrie Epling, Elizabeth Sinclair, Douglas S. Hawkins, Holcombe E. Grier, Katherine A. Janeway, Phillip Barnette, (unknown), Mark Krailo, Donald A. Barkauskas, Katherine K. Matthay, Richard B. Womer, Richard Görlick, Stephen L. Lessnick, Crystal L. Mackall, Steven G. DuBois	17
19	Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming 2011 ·Cancer Research ·Brian E. Schwartz, Matthias D. Hofer, Madeleine E. Lemieux, (unknown), Michael J. Cameron, Nathan West, Elin S. Agoston, Nicolas Reynoird, Saadi Khochbin, Tan A. Ince, Amanda L. Christie, Katherine A. Janeway, Sara O. Vargas, Antonio R. Pérez‐Atayde, Jon C. Aster, Stephen E. Sallan, Andrew L. Kung, James E. Bradner, Christopher A. French	156
20	Pediatric KIT –Wild-Type and Platelet-Derived Growth Factor Receptor α–Wild-Type Gastrointestinal Stromal Tumors Share KIT Activation but not Mechanisms of Genetic Progression with Adult Gastrointestinal Stromal Tumors 2007 ·Cancer Research ·Katherine A. Janeway, Bernadette Liegl, Amy Harlow, Claudia Le, Antonio R. Pérez‐Atayde, Harry Kozakewich, Christopher L. Corless, Michael C. Heinrich, Jonathan A. Fletcher	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact